Key Takeaways
- HSBC moved Eli Lilly (LLY) from Hold to Reduce rating, lowering price target from $1,070 to $850
- HSBC analyst Rajesh Kumar believes the stock has reached perfection pricing following a 20% yearly advance
- The bank reduced its obesity medication market projection to $80–120bn by 2032, significantly below the $150bn+ Street consensus
- Key worries include orforglipron launch assumptions, pricing dynamics, and dependence on cash-paying customers
- Shares declined 1.6% to $972.51 after the rating change; competitor Novo Nordisk (NVO) has fallen 52% in the same timeframe
Eli Lilly has enjoyed an impressive rally. While its primary competitor Novo Nordisk has shed more than half its market value, LLY shares have climbed 20% over the trailing twelve months, positioning it as the apparent champion in the weight-loss pharmaceutical battle. However, HSBC believes investors may be overly optimistic.
Tuesday saw HSBC analyst Rajesh Kumar shift his stance on Lilly to Reduce from Hold while simultaneously trimming his price objective to $850 from $1,070. Shares responded by falling 1.6% to $972.51.
Kumar’s central thesis is straightforward: the stock has achieved perfect pricing, leaving minimal margin for disappointment.
The analyst’s bearish view centers on three primary issues. First is the actual size of the obesity pharmaceutical market. HSBC’s revised forecast places the total addressable market at $80–120 billion by 2032. This represents a substantial discount to the $150 billion-plus projections widely circulated across Wall Street.
This discrepancy carries weight. A more constrained market potential translates to reduced revenue expansion opportunities compared to what’s currently reflected in Lilly’s stock price.
Questions Surround Orforglipron Launch Forecasts
The second issue involves Lilly’s forthcoming oral obesity treatment, orforglipron. Set to debut later this year, the medication has sparked considerable enthusiasm — Wall Street consensus anticipates 2026 revenues between $1.1 billion and $1.3 billion.
HSBC challenges these projections as overly ambitious. Kumar suggested that “the compliance and persistence of these drugs might disappoint,” while observing that current estimates seem tied to a $1.5 billion inventory accumulation Lilly has already completed in preparation for launch.
Stockpiling inventory demonstrates corporate confidence. However, it simultaneously elevates risk exposure should the product fail to meet expectations.
Mounting Pricing Headwinds
The third concern centers on pricing dynamics. Lilly confronts anticipated price reductions in 2026 due to intensifying competition, with HSBC highlighting “rising working capital intensity” and weakening “rebate dynamics” as red flags.
Kumar also drew attention to the divergence between Lilly’s and Novo Nordisk’s forward guidance — a puzzle for many market participants. His interpretation suggests Lilly’s superior performance stems largely from the cash-pay segment, where patients pay directly rather than through insurance coverage.
This distribution channel exhibits greater vulnerability to economic fluctuations and, according to HSBC’s assessment, may face disruption from AI-driven labor market transformations.
HSBC maintains a constructive outlook on the broader healthcare sector for the coming quarter. Nevertheless, Kumar considers Lilly’s risk-reward profile unattractive at present valuation levels.
LLY traded at $972.51 when the downgrade was issued, representing more than $120 premium to HSBC’s revised $850 price objective.
Get 3 Free Stock Ebooks
Discover top-performing stocks in AI, Crypto, and Technology with expert analysis.
- Top 10 AI Stocks - Leading AI companies
- Top 10 Crypto Stocks - Blockchain leaders
- Top 10 Tech Stocks - Tech giants
